Ole Andreas Halvorsen's Net Worth

$2.18 Billion

Estimate Recalculated Feb 22, 2024 09:07PM EST

Who is Ole Andreas Halvorsen?

Ole Andreas Halvorsen has an estimated net worth of $2.18 Billion. This is based on reported shares across multiple companies, which include Adaptive Biotechnologies Corp, Roivant Sciences Ltd., Wayfair Inc., Urovant Sciences Ltd., Myovant Sciences Ltd., FIRST DATA CORP, Arbutus Biopharma Corp, APi Group Corp, Axovant Gene Therapies Ltd., BridgeBio Pharma, Inc., Amylyx Pharmaceuticals, Inc., Zentalis Pharmaceuticals, Inc., RayzeBio, Inc., Editas Medicine, Inc., Inhibrx, Inc., PROCEPT BioRobotics Corp, 4D Molecular Therapeutics, Inc., Rallybio Corp, Ginkgo Bioworks Holdings, Inc., FIGS, Inc., and Frazier Lifesciences Acquisition Corp.

SEC CIK

Ole Andreas Halvorsen's CIK is 0001133006

Past Insider Trading and Trends

2019 was Ole Andreas Halvorsen's most active year for acquiring shares with 72 total transactions. Ole Andreas Halvorsen's most active month to acquire stocks was the month of May. 2022 was Ole Andreas Halvorsen's most active year for disposing of shares, totalling 22 transactions. Ole Andreas Halvorsen's most active month to dispose stocks was the month of August. 2022 saw Ole Andreas Halvorsen paying a total of $312,238,236.29 for 300,884,319 shares, this is the most they've acquired in one year. In 2020 Ole Andreas Halvorsen cashed out on 19,163,712 shares for a total of $573,887,078.58, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Amylyx Pharmaceuticals, Inc. (AMLX) Snapshot price: $15.315

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-10.26%
-1.40M
$29.80
-$41,719,639.31
12.24M
Sep 8 - Sep 9
Form 4
7.17M
$19.00
$43,700,000.00
7.17M
Jan 11 - Nov 11
Form 3
0
0
No matching records found

Adaptive Biotechnologies Corp (ADPT) Snapshot price: $3.575

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-3.23%
-1.00M
$55.65
-$55,650,000.00
29.99M
Dec 14
Form 4
-7.46%
-2.50M
$49.52
-$123,787,500.00
30.99M
Nov 11
Form 4
-7.46%
-2.50M
$49.52
-$123,787,500.00
30.99M
Nov 11
Form 4
-12.79%
-4.91M
$24.98
-$122,706,039.29
33.49M
Jan 28
Form 4
-12.79%
-4.91M
$24.98
-$122,706,039.29
33.49M
Jan 28
Form 4
+2,595.20%
36.98M
$20.00
38.41M
Jul 1
Form 4
+2,595.20%
36.98M
$20.00
38.41M
Jul 1
Form 3
0
0
Form 3
0
0
No matching records found

Zentalis Pharmaceuticals, Inc. (ZNTL) Snapshot price: $11.33

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-11.25%
-500.00K
$50.50
-$25,250,000.00
3.94M
Dec 1
Form 4
+19.50%
725K
$18.00
$13,050,000.00
4.44M
Apr 7
Form 3
0
0
No matching records found

RayzeBio, Inc. (RYZB) Snapshot price: $62.125

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
6.64M
$18.00
6.64M
Sep 19
Form 4
6.64M
$18.00
6.64M
Sep 19
Form 3
0
0
Form 3
0
0
No matching records found

Editas Medicine, Inc. (EDIT) Snapshot price: $7.155

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4/A
5.46M
5.46M
Feb 8 - Feb 8
Form 4
5.46M
5.46M
Feb 8 - Feb 8
Form 3
0
0
No matching records found